Thus, and although much less is known about their role in tumoral cells, it seems that somatostatin and SSAs can reduce VEGF production from some types of tumoral cells such as gliomas [25], gastric carcinomas [26] or pancreatic cancer [27–29], acting through the sst2 receptor subtype [27–29]. Here, SST is linked to gastric carcinoma.